Date | Title | Description | |
---|---|---|---|
03 Jan 2022 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 | Download |
28 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 | Download |
20 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 | Download |
17 Dec 2021 | On business and financial situation | ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia | Download |
13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |